Pharmacological enhancement of prefrontal D 1 dopamine receptor function remains a promising therapeutic approach to ameliorate schizophrenia-spectrum working memory deficits, but has yet to be rigorously evaluated clinically. This proof-of-principle study sought to determine whether the active enantiomer of the selective and full D 1 receptor agonist dihydrexidine (DAR-0100A) could attenuate working memory impairments in unmedicated patients with schizotypal personality disorder (SPD). We performed a randomized, doubleblind, placebo-controlled trial of DAR-0100A (15 mg/150 ml of normal saline administered intravenously over 30 min) in medication-free patients with SPD (n ¼ 16) who met the criteria for cognitive impairment (ie, scoring below the 25th percentile on tests of working memory). We employed two measures of verbal working memory that are salient to schizophrenia-spectrum cognitive deficits, and that clinical data implicate as being associated with prefrontal D 1 availability: (1) the Paced Auditory Serial Addition Test (PASAT); and (2) the N-back test (ratio of 2-back:0-back scores). Study procedures occurred over four consecutive days, with working memory testing on Days 1 and 4, and DAR-0100A/placebo administration on Days 2-4. Treatment with DAR-0100A was associated with significantly improved PASAT performance relative to placebo, with a very large effect size (Cohen's d ¼ 1.14). Performance on the N-back ratio was also significantly improved; however, this effect rested on both a non-significant enhancement and diminution of 2-back and 0-back performance, respectively; therefore interpretation of this finding is more complicated. DAR-0100A was generally well tolerated, with no serious medical or psychiatric adverse events; common side effects were mild to moderate and transient, consisting mainly of sedation, lightheadedness, tachycardia, and hypotension; however, we were able to minimize these effects, without altering the dose, with supportive measures, eg, co-administered normal saline. Although preliminary, these findings lend further clinical support to the potential of D 1 receptor agonists to treat schizophrenia-spectrum working memory impairments. These data suggest a need for further studies with larger group sizes, serum DAR-0100A levels, and a more comprehensive neuropsychological battery.
INTRODUCTION
Cognitive deficits are a critical determinant of functional outcomes in schizophrenia and related psychiatric conditions (Green, 2006 ), yet they remain relatively resistant to standard treatment (Keefe, 2007) approaches. A number of experimental agents with preclinical promise have, unfortunately, yielded disappointing results in clinical trials (Buchanan et al, 2011; Egan et al, 2013; Harvey, 2009; Velligan et al, 2012) . Numerous studies have established that compromised working memory function is a central component of schizophrenia-spectrum cognitive deficits (Goldman-Rakic, 1994) . Therefore, targeting the mediators of working memory, particularly those with pathophysiological significance, is an essential approach to develop effective therapeutics for the cognitive impairments of the schizophrenia spectrum.
There is an abundant experimental literature demonstrating the critical role of the D 1 dopamine receptor in the modulation of working memory in the dorsolateral prefrontal cortex (DLPFC) (Goldman-Rakic et al, 2004) . Furthermore, frontocortical D 1 receptor availability has been shown to be relatively increased in antipsychotic-naive patients with schizophrenia; and this has been proposed to reflect compensatory, albeit insufficient, D 1 upregulation in response to possible cortical hypodopaminergia in the schizophrenia spectrum (Abi-Dargham, 2003) . Therefore, pharmacological enhancement of D 1 receptor activity is a highly promising therapeutic mechanism for the amelioration of schizophrenia-spectrum cognitive deficits. Importantly, however, there have been barriers to the development of pharmacological agents with D 1 agonist activity (Mailman et al, 2001; Zhang et al, 2009) , and therefore enhancement of working memory in the schizophrenia spectrum via direct D 1 stimulation has yet to be studied definitively in the clinical setting.
Although it was recognized by the late 1970s that there were two major populations of dopamine receptors (Garau et al, 1978; Kebabian and Calne, 1979) , the prototypical D 1 agonist SKF38393 (Setler et al, 1978) was of limited experimental utility largely due to the fact that it had low intrinsic activity (Gilmore et al, 1995; Watts et al, 1993 Watts et al, , 1995 . It was a decade before dihydrexidine (DHX), the first selective and full D 1 agonist, was described (Lovenberg et al, 1989) . DHX exhibits more than ten-fold higher affinity and potency at the D 1 receptor than dopamine, and full intrinsic activity in every system in which it has been tested to date (Brewster et al, 1990; Mottola et al, 1992; Salmi et al, 2004; Watts et al, 1995) . DHX has about ten-fold selectivity for the D 1 vs the D 2 receptor (Mottola et al, 1992) , and at the D 2 receptor it is functionally selective, with high bias for regulation of adenylate cyclase vs potassium channels (Gay et al, 2004; Kilts et al, 2002; Mailman, 2007; Mottola et al, 2002) . When DHX entered development in 2002, it was assigned the label DAR-0100, and the active (both at D 1 and D 2 ) diastereomer (Knoerzer et al, 1994; Mottola et al, 1996) was assigned the label DAR-0100A.
Although discovered more than 20 years ago, DHX remains the prototypical full, selective D 1 agonist. DHX has been shown to enhance working memory in animal models in normal and pathological states (Arnsten et al, 1994; Schneider et al, 1994) , yet clinical testing of DHX has been limited for at least two reasons: First, the drug has a very short duration of action, and can only be given parenterally in currently available formulations. Second, an initial Phase I/IIa study in Parkinson's disease subjects showed some efficacy, but also resulted in profound hypotension (Blanchet et al, 1998) . Later developmental work, however, demonstrated that the drug could be used safely (George et al, 2007) , and this provided the foundation for an NIMHsponsored Cooperative Drug Development Group project (awarded to our Columbia University collaborators) that synthesized the active enantiomer, DAR-0100A, and obtained an Investigational New Drug application to optimize clinical infusion parameters, and examine the effects of DAR-0100A on cognitive function in schizophrenia and related conditions. Our group subsequently obtained an Investigational New Drug application to examine DAR-0100A in the schizophrenia spectrum, as well.
Evaluating the efficacy of novel agents (eg, DAR-0100A) to attenuate cognitive impairment in schizophrenia is made difficult by factors such as concurrent/past medication, stage of illness and prior psychotic episodes, relatively global cognitive deficits, and chronic psychosocial stress related to profound functional impairment. One approach to addressing these confounds is to study patients with schizotypal personality disorder (SPD), a schizophreniaspectrum condition that manifests qualitatively similar working-memory deficits that are narrower in scope and severity (Mitropoulou et al, 2002 (Mitropoulou et al, , 2005 . Our prior studies of patients with SPD have shown dopaminergically mediated improvement of schizophrenia-spectrum cognitive deficits. This effect was first demonstrated with amphetamine (Siegel et al, 1996; Kirrane et al, 2000) which increases catecholaminergic activity globally, and more recently with pergolide (McClure et al, 2010) Therefore, we have examined whether treatment with DAR-0100A could ameliorate the schizophrenia-spectrum cognitive deficits of unmedicated patients with SPD using two tests of verbal working memory: the Paced Auditory Serial Addition Test (PASAT) and N-back tests. We specifically selected these two tests of working memory because they consistently reveal cognitive impairments of patients with SPD (Mitropoulou et al, 2002; McClure et al, 2008) , and because of the relationship between greater frontocortical D 1 availability (which may reflect D 1 understimulation) and degree of impairment of PASAT (Thompson et al, 2014) and N-back performance (AbiDargham et al, 2002) in the schizophrenia spectrum. Furthermore, among a broad array of cognitive function tests, we have shown that PASAT performance accounts for a substantial component of the variance between SPD patients and healthy controls, implicating the salience of this test for assessing cognitive impairment in SPD (Mitropoulou et al, 2005) .
MATERIALS AND METHODS

Participants
The study was approved by the Institutional Review Boards of the Mount Sinai Medical Center and the James J. Peters Bronx Veterans Affairs Medical Center. Participants provided written informed consent after explanation of study procedures. Participants were recruited from the local population through newspaper advertisements and the internet. All participants underwent a medical clearance, consisting of a medical history by a study physician, physical exam, basic blood and urine tests, and electrocardiogram. All participants were free of significant medical/neurological problems, and were not pregnant or nursing. Sixteen participants (11 male (M) 5 female (F); mean age ¼ 35.9 years (SD ¼ 12.2, range ¼ 20-55) met the criteria for SPD. The Structured Clinical Interview for DSM-IV Axis I Disorder was used for Axis I diagnoses, and the Structured Interview for DSM-IV Personality Disorders was used for Axis II diagnoses.
Participants with active suicidal ideation, as well as participants who met the criteria for major psychotic disorders (such as bipolar I or schizophrenia), or participants who currently met the DSM-IV-TR criteria for a major depressive episode were excluded from participation and referred for appropriate treatment. Participants had neither abused illicit substances nor alcohol within the past 6 months, nor had a past history of substance dependence. All patients were negative on a urine toxicology screen to rule out current use of common substances of abuse. Participants were excluded if they did not exhibit cognitive impairment, as defined by scoring at or below the 25th percentile of published scores for healthy participants on at least one test of working-memory battery that included the PASAT, N-back test, and Dot test. Of note, the Dot test-a measure of visuospatial working-memory-was originally included as a secondary measure; however, too few patients completed the Dot test, and therefore it was ultimately not included in our final analyses.
Treatment Design
The protocol occurred over four consecutive days that included baseline cognitive testing (see Cognitive Assessments, below), and urine drug (and pregnancy, for women of child-bearing age) screening on Day 1. On days 2-4, an intravenous catheter was placed by a qualified nursing staff member of the Clinical Research Unit of the Mount Sinai Medical Center, and either DAR-0100A (15 mg/150 ml of normal saline (NS)) or placebo (150 ml of NS) was intravenously infused at a rate of 300 ml/h. Additionally, 133 ml of intravenous. NS was co-infused (beginning 5 min prior to and ending 5 min after DAR-0100A/placebo infusion) at a rate of 200 ml/h. Repeat cognitive testing (beginning B20 min after the start of DAR-0100A/placebo infusion) was performed on days 2 and 4. Serial liver function testing was also performed because transient, clinically insignificant transaminase increases had been seen in three subjects in early studies at Columbia.
Participants were randomized in a double-blind manner to receive either DAR-0100A or placebo throughout the three days of infusion. Day 1 procedures (other than baseline liver function testing) took place in the research office of the Mood and Personality Disorders Group. Procedures for Days 2-4 occurred in the Clinical Research Unit of the Mount Sinai Medical Center. On days 2-4, participants were semi-recumbent in a standard hospital bed with the upper body raised to B451 during cognitive testing. Participants were monitored by a study physician and the Clinical Research Unit nursing staff; vital signs were obtained every 5 min during DAR-0100A/placebo infusion, and every 15 min for 1 h after completion of the infusion.
Cognitive Assessments
Rationale for choice of cognitive assessments. Based on our prior studies in SPD and schizophrenia, we selected two tests of verbal working memory that we have demonstrated are impaired in SPD (McClure et al, 2008; Mitropoulou et al, 2002 Mitropoulou et al, , 2005 , and that evidence suggests are related to frontocortical D 1 availability (Abi-Dargham et al, 2002; Thompson et al, 2014) : (1) the PASAT ; and (2) the N-back test. (As indicated above, the Dot test-a measure of visuospatial working memory-was originally included; however, data were available for too few participants.) Of note, we did not include neuropsychological tests that formally assess cognitive processes other than working memory (eg, attention, executive function, declarative memory, processing speed) given the short half-life of DAR-0100A, and the anticipated narrow window of opportunity for identifying a therapeutic effect.
PASAT. The PASAT is a test of auditory/verbal working memory. Participants are presented with a series of numbers (50 numbers at the rate of one digit per 2 s) by audiotape, and are asked to add each adjacent pair of numbers and report the sum. The total number of correct responses (range 0-49) was computed. We then calculated ratio scores (post-treatment minus baseline/baseline) in order to control for baseline differences in performance. This ratio score was the dependent variable in this study.
N-back test. The N-back test is an assessment of visual/ verbal working memory. We employed two conditions: (a) the 0-back-a control condition that primarily assesses sustained attention-in which participants are instructed to press a target button when presented with the letter 'X'; and (b) the 2-back-which requires working memory as well as sustained attention-in which participants are instructed to press a target button when the letter appearing is the same as the letter that appeared two previous screens back. In order to account for individual differences in attentional functioning, N-back test scores are represented in terms of a 2-back : 0-back ratio. We again calculated ratio scores (posttreatment minus baseline/baseline), in order to control for baseline differences in performance. This ratio score was the dependent variable.
Data Analysis
Between-group t-tests were used to examine potential group (DAR-0100A and placebo) differences of baseline scores and percent change scores (post-treatment minus pre-treatment). A two-group chi-square test was used to examine potential group differences of the baseline gender ratios.
RESULTS
The average age of the 16 participants (11 M, 5 F) who were diagnosed with SPD and completed the study was 35.9 years (SD ¼ 12.2, range ¼ 20-55) ( Table 1 ). The DAR-0100A (n ¼ 8) and placebo (n ¼ 8) groups were comparable with respect to age and gender (Table 1 ). The two groups did not differ significantly on baseline cognitive scores ( Table 2) .
Comparisons of change scores of our tests of verbal working memory between the two groups are illustrated in Table 2 . (Note that one of the participant's N-back data in the DAR-0100A group was lost owing to computer error, D 1 agonist (DAR-0100A) and working memory in SPD DR Rosell et al and therefore could not be included in the N-back analysis.) Compared with placebo (Figure 1 ), the DAR-0100A group exhibited significantly greater improvement in the PASAT (t ¼ À 2.27, df ¼ 14, p ¼ 0.04), with a very large effect size (Cohen's d ¼ 1.14).
The effect of DAR-0100A treatment on N-back performance was less clear than that of the PASAT, however. As shown in Table 2 , the N-back ratio was significantly improved in the DAR-0100A group relative to placebo (t ¼ À 2.23, df ¼ 13, p ¼ 0.04). Similar to the effect on the PASAT, improvement of the N-back ratio was associated with a very large effect size (Cohen's d ¼ 1.14). However, this effect on the N-back ratio was determined by both a non-significant improvement, with a moderate effect size (Cohen's d ¼ 0.46), in 2-back performance, as well as a non-significant decrease in 0-back performance, also with a moderate effect size (Cohen's d ¼ À 0.57). Given the contribution of the nonsignificant decrease in 0-back performance to the improvement of the N-back ratio, the significance of improved N-back ratio performance is less clear than that of the PASAT. We suspect that side effects may have non-specifically led to a possible diminution of non-delayed cognitive processes that underlie 0-back performance. Improvement of N-back ratio performance may suggest DAR-0100A enhanced working memory despite some attenuation of non-delayed perceptual/attentional processes.
DAR-0100A was relatively well tolerated, with no clinically significant adverse events. Side effects were mild to moderate and transient, consisting of lightheadedness, sedation, subjective facial flushing, subjective racing heart, moderate tachycardia, and clinically insignificant decreases in systolic blood pressure. No immediate or delayed psychiatric side effects were associated with DAR-0100A treatment, and no liver function testing changes occurred in any of the participants.
DISCUSSION
This is the first published study to examine the effects of a selective D 1 agonist on salient measures of working memory function in a clinical population with schizophrenia-spectrum cognitive deficits without important confounds such as concurrent psychotropic medication, psychosis, substance abuse, and pervasive functional impairment. While our findings must be interpreted with caution, they do suggest that pharmacological enhancement of D 1 receptor activity may mitigate schizophrenia-spectrum working memory impairments. Important limitations of our study that must be taken into consideration are small sample size, the lack of serum drug concentrations, and the fact that improvement on the N-back ratio in the DAR-0100A-treated group was due to a non-significant improvement in the 2-back and a non-significant decline of 0-back performance.
Treatment with DAR-0100A, under our optimized infusion parameters, was not associated with any dose-limiting side effects or significant medical sequelae. DAR-0100A was generally well tolerated, and side effects were transient, consisting primarily of facial flushing, lightheadedness, sedation, subjective racing heart, as well as minor increases in heart rate, and clinically insignificant hypotension, all of which resolved prior to or soon after completion of drug infusion. No serious cardiovascular or hepatic-function abnormalities occurred, and there were no acute or delayedonset psychiatric side effects. Specifically, there was no evidence of depression, mania, psychosis, agitation, anxiety, or confusion/disorientation on the days of drug infusion or at a 1-2-week follow-up. The first reported studies of DHX effects on cognitive function were performed in primates, and demonstrated cognitive enhancement in young, aged, and reserpinetreated animals (Arnsten et al, 1994) , as well as chronic, low-dose MPTP-treated primates (Schneider et al, 1994) . Furthermore, in rodent models, DHX also was shown to improve both native processes and reverse scopolamineinduced deficits (Steele et al, 1997) , as well as attenuate PCP-induced deficits of NMDA-R activity (Lei et al, 2009) .
As noted earlier, there have been two prior reported clinical studies with DHX: The first, in Parkinson's disease (Blanchet et al, 1998) , showed anti-parkinsonian efficacy in one of four patients who received the highest dose (35 mg/ 15 min, intravenously.), but clinically significant hypotension occurred that was dose limiting despite lengthening the infusion time from 15 to 120 min. Almost a decade later, administration of a single, subcutaneous dose of 20 mg of DHX was found to be well tolerated in patients with schizophrenia who were medicated with risperidone (George et al, 2007) . In this latter study, DHX treatment was associated with increases in prefrontal, as well as temporal and parietal cortical, perfusion , and a significant improvement on a 2-back task, but only on the second day after treatment (Johnson, George, et al, personal communication) . The latter result is difficult to resolve because of experimental confounds (eg, neuropsychological testing delayed for many hours after drug, etc.). The current study had several design advantages: First, we used a somewhat higher active dose (ie, 15 mg of the active enantiomer DAR-0100A rather than 20 mg of the racemate); cognitive testing was done soon after completion of DAR-0100A infusion; neuropsychological tests were used that were particularly salient to schizophrenia-spectrum working-memory deficits; and patients were not receiving concurrent neuroleptics, nor did they suffer from pervasive functional impairment.
As with any drug, the question is whether the effect we have found with DAR-0100A can be ascribed solely to the activation of D 1 receptors. There are two primary off-target receptors that should be considered in the actions of DHX: the dopamine D 2, and the a 2 -adrenergic receptor (Mottola et al, 2002) . The one of greater importance is the D 2 as DHX is only 10-fold D 1 : D 2 selective (Mottola et al, 2002) . As noted earlier, however, DHX has unique functionally selective properties at D 2 receptors, having full agonist effects at D 2 -dependent inhibition of adenylate cyclase vs little or no intrinsic activity at G protein-coupled inwardly rectifying potassium channels (Gay et al, 2004; Kilts et al, 2002; Mailman, 2007; Mottola et al, 2002) . This probably explains why, even at very high doses, DHX does not have amphetamine-like actions in vivo (Darney et al, 1991) as would be expected from a drug activating both D 1 and D 2 receptors. Moreover, the turning induced by DHX in unilateral 6-OHDA rats is completely blocked by selective D 1 antagonists, but not decreased by D 2 antagonists (in contrast to the typical D 2 : D 1 agonist apomorphine where each type of antagonist will attenuate the turning). In addition, DHX lessens psychomotor activity (an effect attenuated by D 1 , but not by D 2 , antagonists), actually antagonizing amphetamine-induced increases in motor activity, and causes immediate early-gene expression changes in the medial prefrontal cortex that are sensitive to D 1 but not D 2 antagonists (Isacson et al, 2004) .
The other potentially important off-target locus is the a 2 -adrenergic receptor. It is not known what the functional characteristics of DHX are at this receptor, but we do know the drug is B50-fold D 1 : a 2 selective. PET studies have shown that D 2 occupancy is unlikely to be important with clinical doses of DHX (Slifstein et al, 2011) , and because the a 2 -adrenergic affinity is five times lower than the D 2 , it seems unlikely that the current data were affected by a 2 -adrenergic effects. Nonetheless, more detailed future studies with DHX and with newer D 1 agonists will be needed to provide a conclusive test of this hypothesis.
It is also important to take into consideration that the animal studies of working-memory functional effects of D 1 agonists demonstrate an inverted-U-shaped dose-response curve rather than a plateauing curve. Based on the published pharmacology of DAR-0100A in humans, the doses we used result in very low blood concentrations that are almost certainly in the ascending phase of the doseresponse curve of this drug, being less than those that cause cognitive enhancement in non-human primates (Arnsten et al, 1994; Schneider et al, 1994) . Nonetheless, this assumption will need to be tested in further studies in which a therapeutic range for DAR-0100A and other D 1 agonists is determined, as this has significant implications for the clinical utility of this class of drug.
Although there have been many selective full D 1 agonists discovered during the past 25 years, only two compounds (DHX and ABT-431) have resulted in reports of clinical studies. ABT-431 is a prodrug of A-86929 that has in vitro pharmacology almost identical to DHX (Michaelides et al, 1995; Mottola et al, 1992) . The data from both compounds allow us to speculate on other side effects that are attributed to dopamine agonists as a general class, including nausea, the exacerbation of psychosis, and drug-abuse-related behaviors. There is a sizable literature that suggests that nausea and psychosis exacerbation are largely mediated by D 2 receptors. The issue of drug abuse liability is more complex as some studies in murine species suggest D 1 agonists have potential liability (Graham et al, 2007) . On the other hand, it has been reported that ABT-431 actually decreased cocaine craving (Giardina and Williams, 2001) , suggesting that clinically this will not be problematic.
A number of important study limitations need to be addressed: The sample size was modest; we did not assess serum drug concentrations; and cognitive domains other than those related to working memory (such as attention, executive function, and declarative memory) were not examined. Although we did collect serial blood samples during the 2nd day of drug/placebo infusion, these will not be analyzed until a later date once we have accrued enough samples to send out for analysis. In our current funded study, however, we are assessing a broad array of cognitive processes, and therefore we will be able to assess the specificity of effects of DAR-0100A.
An additional matter worthy of addressing is that improvement of the N-back ratio was due to non-significant increases and decreases, respectively, of 2-back and 0-back performance. Taking into account that performance on the PASAT was significantly improved in the DAR-0100A-treated group, a plausible explanation for the mixed result on the N-back is that working-memory function may have been enhanced, despite a possible attenuation of D 1 agonist (DAR-0100A) and working memory in SPD DR Rosell et al non-delayed attentional/perceptual processes. It is also possible that the N-back (a visual, verbal working-memory task) is not as sensitive to enhancement by DAR-0100A as is the PASAT (an auditory, verbal working-memory task). This is consistent with our recent finding that frontocortical D 1 receptor availability in patients with SPD was negatively correlated with PASAT performance, but not that of the 2-back (Thompson et al, 2014) . We speculate that any attenuation of non-delayed attentional/perceptual processes (eg, 0-back performance) in the DAR-0100A group may have been due to side effects such as sedation, and lightheadedness. However, it is also possible that the 15-mg dose was too high and eroded cognitive improvement, given the inverted-U dose-response function of D 1 agonists. This issue could be addressed in future studies where side effects are minimized by supportive measures, or lower doses are assessed for effects on cognition. Although side effects were mild, transient, and without significant clinical impact, their potential for breaking the blind is an additional study limitation. Anecdotal evidence from our Columbia colleagues (Girgis, personal communication) suggests participants were unable to correctly identify whether they were receiving DAR-0100A or placebo. Furthermore, in this study, the physician who performed clinical monitoring did not administer the workingmemory tests, and research personnel who did administer neuropsychological testing were not monitoring the side effects and vital signs. Nevertheless, we cannot rule out the possibility that failure to absolutely maintain the blind may have confounded our results.
In an effort to confirm our findings and address these limitations, we are currently conducting a large, randomized, placebo-controlled, cross-over trial of DAR-0100A in patients with SPD using a more comprehensive neuropsychological battery of working memory and verbal learning (as well as those assessing more basic cognitive processes) and serial assessment of serum drug levels. Even within the current limitations, the findings of this study should provide an impetus for the discovery and development of novel D 1 agonists that would have improved pharmacokinetic properties, including longer half-life and greater oral bioavailability, which may ultimately be helpful in psychiatric and neurologic disorders characterized by workingmemory impairment, including schizophrenia-spectrum disorders and attention deficit-related disorders.
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